Ryali Sriram 4

What Happened

• Ryali Sriram, Chief Financial Officer of Caribou Biosciences (CRBU), received equity awards on February 20, 2026: 55,000 restricted stock units (RSUs) and 247,500 stock option-type derivative awards. Both grants were issued at $0.00 per share, so no cash changed hands at grant.

Key Details

• Transaction date: 2026-02-20. Transaction code: A (grant/award).
• Grants: 55,000 RSUs (F1) and 247,500 options/derivative awards (F2), grant price $0.00; total immediate value shown as $0 in the filing.
• Vesting for RSUs (F1): vest in four equal annual installments beginning Feb 20, 2027; each tranche will be settled in stock within 30 days of the vesting date, contingent on continued service.
• Vesting for options (F2): 1/48 of the option vests monthly (monthly vesting over 4 years), fully vested Feb 20, 2030, subject to continued service.
• Shares owned after the reported transactions: not specified in the provided filing details.
• Filing timeliness: filing date equals transaction date (2026-02-20); no late filing indicator provided.

Context

• These were compensation grants, not open-market purchases or sales. Grants at $0 are typical equity compensation to executives and do not represent an immediate cash outlay or sale of stock.
• RSUs convert to actual shares only as they vest; options will vest monthly and may require exercise later (which could have a strike price and tax implications when exercised or sold). These awards are conditional on continued employment and do not by themselves indicate buying or selling sentiment.